Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
Despite the availability of a lot of effective disease-modifying drugs, multiple sclerosis (MS) (in particular the progressive forms) still represents an important unmet medical need, because of issues in terms of effectiveness, duration of response, safety, and patient compliance. An increasing body of evidence from randomized clinical trials and real-world data suggest that rituximab is a highly effective alternative in both relapsing and progressive MS, with a low discontinuation rate, related to a good benefit/risk profile, and a good compliance. To date, the use of rituximab in patients with multiple sclerosis is not in accordance with the authorized product information (off-label use). However, the use of this medicine is widespread in several countries, and in some cases, it is the most commonly used disease-modifying drug for MS subtypes. This use could be officially recognized by national regulatory authorities, according to specific procedures, to ensure equal access for patients to a safe and effective option..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in Immunology - 12(2021) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Serena Brancati [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Disease-modifying drugs |
|---|
| doi: |
10.3389/fimmu.2021.661882 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ057328544 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ057328544 | ||
| 003 | DE-627 | ||
| 005 | 20230308211256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2021.661882 |2 doi | |
| 035 | |a (DE-627)DOAJ057328544 | ||
| 035 | |a (DE-599)DOAJ66b39ea17ae140daa7797bc64b329afe | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC581-607 | |
| 100 | 0 | |a Serena Brancati |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Despite the availability of a lot of effective disease-modifying drugs, multiple sclerosis (MS) (in particular the progressive forms) still represents an important unmet medical need, because of issues in terms of effectiveness, duration of response, safety, and patient compliance. An increasing body of evidence from randomized clinical trials and real-world data suggest that rituximab is a highly effective alternative in both relapsing and progressive MS, with a low discontinuation rate, related to a good benefit/risk profile, and a good compliance. To date, the use of rituximab in patients with multiple sclerosis is not in accordance with the authorized product information (off-label use). However, the use of this medicine is widespread in several countries, and in some cases, it is the most commonly used disease-modifying drug for MS subtypes. This use could be officially recognized by national regulatory authorities, according to specific procedures, to ensure equal access for patients to a safe and effective option. | ||
| 650 | 4 | |a multiple sclerosis | |
| 650 | 4 | |a rituximab | |
| 650 | 4 | |a off-label | |
| 650 | 4 | |a regulatory issue | |
| 650 | 4 | |a disease-modifying drugs | |
| 653 | 0 | |a Immunologic diseases. Allergy | |
| 700 | 0 | |a Lucia Gozzo |e verfasserin |4 aut | |
| 700 | 0 | |a Lucia Gozzo |e verfasserin |4 aut | |
| 700 | 0 | |a Laura Longo |e verfasserin |4 aut | |
| 700 | 0 | |a Daniela Cristina Vitale |e verfasserin |4 aut | |
| 700 | 0 | |a Filippo Drago |e verfasserin |4 aut | |
| 700 | 0 | |a Filippo Drago |e verfasserin |4 aut | |
| 700 | 0 | |a Filippo Drago |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Immunology |d Frontiers Media S.A., 2011 |g 12(2021) |w (DE-627)DOAJ000031690 |x 16643224 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2021 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fimmu.2021.661882 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/66b39ea17ae140daa7797bc64b329afe |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fimmu.2021.661882/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1664-3224 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2021 | ||